Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud M: Quantitation out of androgen receptor gene term when you look at the sporadic breast cancers from the real-go out RT-PCR: proof you to MYC try an enthusiastic AR-regulated gene. Carcinogenesis. 2001, 22 (9): 1521-1526. /carcin/twenty-two.nine.1521.

Bratthauer GL, Lininger RA, Guy YG, Tavassoli FA: Androgen and you may the hormone estrogen receptor mRNA reputation in apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.

Gatalica Z: Immunohistochemical study out of apocrine breast lesions. Uniform more than-term from androgen receptor followed by the loss of the hormone estrogen and you can progesterone receptors when you look at the apocrine metaplasia and you can apocrine carcinoma inside the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.

Am J Clin Pathol

Soreide JA, Lea OA, Varhaug JE, Skarstein An excellent, Kvinnsland S: Androgen receptors inside operable breast cancer: reference to most other steroid hormone receptors, correlations to prognostic things and predictive worth to possess aftereffect of additive tamoxifen therapy. Eur J Surg Oncol. 1992, 18 (2): 112-118.

Bayer-Gather IB, Smoller B: Androgen receptors: a good marker to boost susceptibility to own determining breast cancer in body metastasis out of unknown pri, 13 (2): 119-122. /modpathol.3880021.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic hobby and you will health-related effects. J Clin Oncol. 2000, 18 (5): 1135-1149.

Pang ST, Flores-Morales A beneficial, Skoog L, Chuan YC, Nordstedt G, Pousette Good: Regulation from matrix metalloproteinase thirteen phrase because of the androgen inside prostate cancer. Oncol Associate. 2004, 11 (6): 1187-1192.

Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.

Schippinger W, Regitnig P, Dandachi Letter, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Analysis of prognostic importance of androgen receptor phrase in metastatic breast cancer. Virchows Arch. 2006, 449 (1): 24-29. /s00428-00six-0213-six.

Parker RL, Huntsman DG, Lesack DW, Cupples JB, Offer DR, Akbari Yards, Gilks CB: Review from interlaboratory type on the immunohistochemical dedication out-of estrogen receptor status playing with a breast cancer tissues microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Examination of matrix metalloproteinases and their inhibitors inside the cancer of the breast. Br J Malignant tumors. 2007, 96 (6): 903-911. /sj.bjc.6603666.

Narita D, Raica M, Suciu C, Cimpean An excellent, Anghel Good: Immunohistochemical expression off androgen receptor and you will prostate-specific antigen in the cancer of the breast. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.

Egeblad Meters, Werb Z: The latest services towards the matrix metalloproteinases in cancer tumors progression. Nat Rev Malignant tumors. 2002, 2 (3): 161-174. /nrc745.

Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–towards the main phase out-of cancer tumors?. Disease Cell. 2004, 5 (5): 409-410. https://datingranking.net/tr/russian-brides-inceleme/ /S1535-6108(04)00117-5.

Manes S, Llorente Yards, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Age, Martinez Air-conditioning: Brand new matrix metalloproteinase-nine controls this new insulin-such as for example development basis-caused autocrine response in the DU-145 carcinoma muscle. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..

Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel Yards: Release of an intrusion promoter Elizabeth-cadherin fragment by matrilysin and you can stromelysin-step one. J Mobile Sci. 2001, 114 (Pt step one): 111-118.

Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] expression selects having tissue with reduced awareness in order to apoptosis. Neoplasia. 2001, 3 (6): 459-468. /sj.neo.7900190.

CO;2-H

Stetler-Stevenson WG: Matrix metalloproteinases into the angiogenesis: a relocation address to have therapeutic input. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.

Cornelius Los angeles, Nehring LC, Harding Elizabeth, Bolanowski M, Welgus HG, Kobayashi DK, Enter RA, Shapiro SD: Matrix metalloproteinases build angiostatin: effects into the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.

Jiang Y, Goldberg ID, Shi YE: Advanced roles off tissue inhibitors out of metalloproteinases within the cancer. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.